InnovHeart this week announced that it appointed medtech veteran David Wilson as CEO.
Wilson has more than 30 years of experience in medical device industry. He previously served in numerous leadership roles at Johnson & Johnson, including worldwide president of Cordis. Wilson has also served at J&J as president of Mentor, VP of Ethicon R&D and VP of Ethicon Biosurgicals and was president of global plasma at Haemonetics.
“I am excited to join the talented team at InnovHeart at this pivotal time of focus and commitment to significantly advancing transcatheter mitral valve replacement (TMVR) procedures enabled by our transformational Saturn platform,” Wilson said in a news release. “The innovative Saturn technology has the potential to be life-changing for patients with regurgitant mitral valves and I’m eager to further the clinical validation of the trans-septal Saturn system.”
“This is an important time for InnovHeart as we transition from a trans-apical to a trans-septal delivery of the Saturn valve,” InnovHeart Chairperson Keith Dawkins said in the release. “We have been encouraged by the outstanding medium-term results of the trans-apical system, and we fully anticipate that the best-in-class hemodynamics will be reflected in the first-in-human implantation of the same Saturn valve transseptally. David’s range of leadership skills will further enhance the commitment, drive and engineering prowess of the strong InnovHeart team.”